ClinicalTrials.gg
RecruitingNCT07759700BEATUpdated Oct 19, 2026

Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation Trial

An interventional study of LBBA pacing and Conventional pacing in Permanent Atrial Fibrillation and Preserved Ejection Fraction, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Treatment

Updated Oct 19, 2026Now RecruitingFirst site in France+4 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker.

The main questions it aims to answer are:

Does left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications?

Researchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies.

Participants will:

Have a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study

Read the detailed description

The BEAT Study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to compare left bundle branch area pacing with conventional right ventricular pacing as the initial pacing strategy in adults with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an indication for permanent ventricular pacing.

Conventional right ventricular pacing is the standard pacing strategy for patients with bradycardia. The ventricular lead is usually positioned at the right ventricular apex or septum. Although this approach is well established, prolonged right ventricular pacing produces a non-physiological pattern of ventricular electrical activation. The resulting electrical and mechanical dyssynchrony may progressively impair left ventricular function and lead to pacing-induced cardiomyopathy, heart failure, hospitalization, and the need for a subsequent procedure to upgrade the pacing system to biventricular pacing.

Patients with permanent atrial fibrillation who require a pacemaker may be particularly exposed to these complications because they generally have a high burden of ventricular pacing. This applies both to patients with slow atrial fibrillation and to those undergoing atrioventricular node ablation for rapid atrial fibrillation. Although these patients may have preserved left ventricular systolic function at the time of pacemaker implantation, repeated non-physiological ventricular activation could contribute to subsequent deterioration in cardiac function.

Left bundle branch area pacing is a conduction-system pacing technique in which the ventricular lead is advanced through the interventricular septum to stimulate the left bundle branch or the surrounding conduction tissue. By recruiting the heart's intrinsic conduction system, this approach is intended to produce more physiological and synchronous ventricular activation than conventional right ventricular pacing. It may therefore preserve left ventricular function and reduce the clinical consequences associated with long-term ventricular pacing.

Evidence supporting left bundle branch area pacing has increased, particularly in patients with impaired left ventricular function or an indication for cardiac resynchronization. However, long-term randomized evidence remains limited in patients with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an expected high ventricular pacing burden. In particular, the effect of the initial pacing strategy on major clinical events in this population has not been adequately established.

The study hypothesis is that left bundle branch area pacing, compared with conventional right ventricular pacing, will reduce clinically important adverse events over 2 years by limiting pacing-related ventricular dyssynchrony and preventing deterioration in left ventricular function.

A total of 642 participants will be enrolled and randomly assigned in a 1:1 ratio to one of two pacing strategies:

Left bundle branch area pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned within the left bundle branch area through the interventricular septum to capture the cardiac conduction system.

Conventional right ventricular pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned at the right ventricular apex or right ventricular septum.

Randomization will be stratified by participating center and by the indication for pacing: rapid permanent atrial fibrillation requiring atrioventricular node ablation or slow permanent atrial fibrillation. Because the implantation techniques are different and identifiable to the treating clinicians, the study is open label.

Participants will be followed for 24 months after pacemaker implantation. Study assessments will include clinical evaluation, pacemaker interrogation, 12-lead electrocardiography, echocardiography, collection of hospitalizations and cardiac reinterventions, assessment of adverse events, and evaluation of health-related quality of life. Follow-up will include clinical visits approximately 2, 12, and 24 months after implantation and telephone contacts approximately 6 and 18 months after implantation.

Echocardiography will be performed at baseline and at the end of the 2-year follow-up to evaluate changes in left ventricular systolic function and ventricular volumes. Pacemaker interrogation will be used to document device function and the proportion of ventricular pacing. Quality of life will be assessed using the Short Form-36 Health Survey and the Kansas City Cardiomyopathy Questionnaire.

The principal comparison will assess whether left bundle branch area pacing improves the proportion of participants who remain free from all-cause death, unplanned hospitalization for heart failure, and upgrade to biventricular pacing at 2 years. Additional analyses will examine cardiac function, individual clinical events, cardiac reinterventions, device- and procedure-related complications, and changes in quality of life. Unplanned heart failure hospitalizations and upgrades to biventricular pacing will be reviewed by an independent adjudication committee.

The primary analysis will follow the intention-to-treat principle. The study is intended to determine whether a physiological pacing strategy should replace conventional right ventricular pacing as the preferred initial approach for patients with permanent atrial fibrillation, preserved left ventricular function, and a substantial anticipated requirement for ventricular pacing.

02

Conditions studied

  • Permanent Atrial Fibrillation
  • Preserved Ejection Fraction

Keywords

  • atrial fibrillation
  • preserved ejection fraction
  • heart failure
  • pacemaker
  • left-bundle-branch-area pacing
03

In context

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's planned enrollment of 642 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and \<90 years
  • Atrial fibrillation requiring ventricular pacing because of

    1. rapid atrial fibrillation requiring atrioventricular node ablation; or
    2. slow atrial fibrillation i.e. ≤ 50 bpm on admission ).
  • ≥50%.
  • Affiliated person or beneficiary of the French social security scheme
  • Having given their .

Exclusion criteria

Exclusion Criteria:

  • Indication for an implantable cardioverter defibrillator.
  • Presence of a mechanical tricuspid valve
  • Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing
  • \<40 mL/min/1,73m2 with CKD-EPI formula
  • Chronic respiratory failure
  • Serious medical condition with of \<2 years
  • Pregnant or breastfeeding women, women of childbearing age who do not have effective (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
  • Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
642 participants (estimated)

Study arms

  • Experimental
    LBBA pacing

    The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.

    Procedure: LBBA pacing

  • Active comparator
    Conventional pacing

    The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.

    Procedure: Conventional pacing

Interventions

  • ProcedureLBBA pacing

    The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.

  • ProcedureConventional pacing

    The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.

06

What researchers measure

Primary outcomes

  1. Proportion of post-implantation adverse events

    proportion of post-implantation adverse events, combining all-cause mortality, unplanned hospitalization related to heart failure, and upgrade to biventricular pacing.

    Time frame: At two years

Secondary outcomes

  1. Left ventricular ejection fraction

    Left ventricular ejection fraction assessed with echocardiography

    Time frame: At 2 years post-implantation.

  2. Left ventricular end-systolic volume

    Left ventricular end-systolic volume assessed with echocardiography

    Time frame: At 2 years post-implantation

  3. Time to composite outcome

    Time to the first event between death, unplanned hospitalization related to heart failure, and upgrade to biventricular during the 2-year follow-up period

    Time frame: Through study completion, an average of 2 years

  4. Unplanned hospitalization related to heart failure

    Time to unplanned hospitalization for heart failure

    Time frame: During the 2-year follow-up perio

  5. All-cause mortality

    Time to all-cause death

    Time frame: During the 2-year follow-up period

  6. Upgrade to biventricular pacing

    Time to upgrade to biventricular

    Time frame: During the 2-year follow-up period

  7. Complications

    Proportions of pocket hematoma, pneumothorax, lead dislodgment, pacing threshold elevation, pericardial effusion, pocket/wound infection, systemic infection, lead fracture, diaphragmatic stimulation, or pacemaker syndrome

    Time frame: During the 2-year follow-up period

  8. Cardiac reintervention

    Time to cardiac reintervention for upgrade to biventricular pacing or due to a complication

    Time frame: During the 2-year follow-up period

  9. Quality of life : Short Form 36 Questionnaire score

    Evolution at the Short Form 36 Questionnaire score. Minimum score: 0; Maximum score: 100; A higher score indicates better health-related quality of life.

    Time frame: Evolution between baseline and 2 years post-implantation

  10. Quality of life : Kansas City Cardiomyopathy Questionnaire score

    Evolution at the Kansas City Cardiomyopathy Questionnaire score. Minimum: 0 - worst possible heart-failure-related health status; Maximum: 100 - best possible health status, with fewer symptoms and limitations

    Time frame: Evolution between baseline and 2 years post-implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
1 site added — first site in France
Show site
  • CHU Poitiers · Poitiers, France
Oct 19, 2026
Start date
Sep 15, 2026→Oct 15, 2026 (actual)
Oct 19, 2026
Primary completion
Aug 14, 2028→Oct 14, 2028
Oct 19, 2026
Sponsor
Collaborators added: Centre Hospitalier Departemental Vendee; collaborators removed: LA ROCHE SUR YON HOSPITAL
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • CHU Poitiers · Poitiers, France
    Start date Sep 15, 2026→Oct 15, 2026 (now actual)
    Primary completion Aug 14, 2028→Oct 14, 2028
    Sponsor Collaborators added: Centre Hospitalier Departemental Vendee; collaborators removed: LA ROCHE SUR YON HOSPITAL
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07759700
Collaborators
University Hospital, Grenoble, Nouvelles Cliniques Nantaises, Nantes, Centre Hospitalier Universitaire de Besancon, Centre Hospitalier de PAU, Centre Cardiologique du Nord, St Denis, Centre Hospitalier Universitaire de Saint Etienne, Centre Hospitalier Departemental Vendee, Centre Hospitalier Régional d'Orléans, University Hospital, Tours
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Oct 15, 2026
Primary completion
Oct 14, 2028 (estimated)
Completion
Aug 14, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Rodrigue GARCIA, MD, PhD
Contact
sec.rythmologie@chu-poitiers.fr
+33516604089
Céline DELETAGE, MSc
Contact
celine.deletage@chu-poitiers.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion